Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61

Benzinga Newsdesk www.benzinga.com Positive 92.4%

Neg 0% Neu 0% Pos 92.4%

Chardan Capital analyst Daniil Gataulin upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Buy and raises the price target from $14 to $61.